AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Signal peptidase complex catalytic subunit SEC11A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P67812

UPID:

SC11A_HUMAN

Alternative names:

Endopeptidase SP18; Microsomal signal peptidase 18 kDa subunit; SEC11 homolog A; SEC11-like protein 1; SPC18

Alternative UPACC:

P67812; B2RAD7; B4DUL4; H0YK72; H0YK83; O75957; P21378; Q53FQ8

Background:

Signal peptidase complex catalytic subunit SEC11A, known as SEC11A, plays a pivotal role in protein synthesis. As a catalytic component of the signal peptidase complex (SPC), SEC11A is essential for cleaving N-terminal signal sequences from nascent proteins during their translocation into the endoplasmic reticulum. This process is crucial for proper protein folding and functionality, highlighting SEC11A's significance in cellular biology.

Therapeutic significance:

Understanding the role of SEC11A could open doors to potential therapeutic strategies. Its critical function in protein processing within the endoplasmic reticulum suggests that modulation of SEC11A activity could have implications for diseases related to protein misfolding or trafficking.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.